PROJECT SUMMARY This project aims to address the significant problem of bacterial pneumonia in goats, which is a major cause of morbidity and mortality and represents a significant welfare challenge for operations in the United States. Currently, there is only one FDA-approved antibiotic for the treatment of respiratory disease in goats, which requires daily administration. That decreases efficacy in situations where owner compliance with labeled instructions is lacking. To address this problem, the proposed research aims to validate an analytical method for the detection and quantification of tulathromycin residues in caprine liver and conduct a freezer stability study of tulathromycin in caprine liver. The expected outcome is to have a validated LC-MS analytical method for the detection and quantification of tulathromycin residues in caprine liver that will be used for completion of the HFS technical section and future studies to determine tulathromycin residue depletion. The label approval of Draxxin® 25 will make it easier for veterinarians to use tulathromycin in goats with confidence in scientifically based labeled slaughter withdrawal times.